Enzene CEO Himanshu Gadgil touts the benefits of continuous manufacturing for improving affordability and access to biologic therapies

Process intensification improves manufacturing processes at unit, operational, and functional levels to increase productivity — often reducing environmental footprints as well. Continuous biomanufacturing plays a key role in speeding biopharmaceutical products to market. As legacy processes and facilities built around batch processing age out, they are giving way to modern alternatives based on single-use technology, closed operations in open “ballroom” environments, automation, and continuous processing for overall intensified biomanufacturing. In this eBook, BPI’s editor in chief reviews some key journal publications, Enzene CEO Himanshu Gadgil touts the benefits of continuous manufacturing for improving affordability and access to biologic therapies, and BPI associate editor Josh Abbott reports on technical discussions at a process-intensification–focused workshop at the 2024 BioProcess International Europe conference.

Source: https://www.bioprocessintl.com

Date: 26/04/2024

Enzene CEO Himanshu Gadgil touts the benefits of continuous manufacturing for improving affordability and access to biologic therapies

The future begins now

Your biologic deserves the most technologically advanced manufacturing process in the industry. And you deserve a new way to think about strategic partnership. Today is just the beginning.